DOI QR코드

DOI QR Code

Downregulated MicroRNA-133a in Gastric Juice as a Clinicopathological Biomarker for Gastric Cancer Screening

  • Shao, Juan (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • Fang, Peng-Hua (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • He, Biao (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • Guo, Li-Li (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • Shi, Ming-Yi (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • Zhu, Yan (Department of Endocrinology, Clinical Medical College, Yangzhou University) ;
  • Bo, Ping (Key Laboratory of Gerontology, Medical College, Yangzhou University) ;
  • Zhang, Zhen-Wen (Key Laboratory of Gerontology, Medical College, Yangzhou University)
  • Published : 2016.05.01

Abstract

Circulatory miR-133a is a marker shared by several types of cancer. In this study we evaluated the feasibility of using miR-133a levels in gastric juice to screen for gastric cancer. A total of 204 samples of gastric juice and mucosa from gastric cancer, atrophic gastritis, gastric ulcer, superficial gastritis and healthy cases were collected by gastroscopy. The results showed that miR-133a levels in gastric juice and carcinoma tissues of patients with gastric cancer were significantly downregulated and positively correlated. Moreover, miR-133a in gastric juice has high operability, high reliability, high sensitivity, high specificity and relative stability, fit for clinical diagnosis of gastric cancer.

Keywords

MicroRNA-133a;down-regulation;gastric juice;gastric cancer

Acknowledgement

Supported by : National Natural Scientific Fund of China

References

  1. Calin GA, Sevignani C, Dumitru CD (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 101, 2999-3005. https://doi.org/10.1073/pnas.0307323101
  2. Cui W, Zhang S, Shan C, Zhou L, Zhou Z (2013). microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J, 280, 3962-74. https://doi.org/10.1111/febs.12398
  3. Dong Y, Zhao J, Wu CW, et al (2013). Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res, 11, 1051-60. https://doi.org/10.1158/1541-7786.MCR-13-0061
  4. Gong Y, Ren J, Liu K, Tang LM (2015). Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1. World J Gastroenterol, 21, 2949-58. https://doi.org/10.3748/wjg.v21.i10.2949
  5. Guo J, Xia B, Meng F, Lou G (2014). miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. Tumour Biol, 35, 1557-64. https://doi.org/10.1007/s13277-013-1215-z
  6. Kinoshita T, Nohata N, Watanabe-Takano H, et al (2012). Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma. Int J Oncol, 40, 1770-8.
  7. Lai C, Chen Z, Li R (2015). MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1. Mol Med Rep, 12, 1473-8. https://doi.org/10.3892/mmr.2015.3545
  8. Lin Y, Ueda J, Kikuchi S, et al (2011). Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol, 17, 4421-8. https://doi.org/10.3748/wjg.v17.i39.4421
  9. Moriya Y, Nohata N, Kinoshita T, et al (2012). Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet, 57, 38-45 . https://doi.org/10.1038/jhg.2011.126
  10. Nohata N, Hanazawa T, Enokida H, Seki N (2012). microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget, 3, 9-21. https://doi.org/10.18632/oncotarget.424
  11. Qiu T, Zhou X, Wang J, et al (2014). MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett, 588, 1168-77. https://doi.org/10.1016/j.febslet.2014.02.054
  12. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  13. Tucci A, Bisceglia M, Rugge M, et al (2007). Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone. Gastrointest Endosc, 66, 881-90. https://doi.org/10.1016/j.gie.2007.03.1052
  14. Wang LK, Hsiao TH, Hong TM, et al (2014). MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS One, 9, 96765. https://doi.org/10.1371/journal.pone.0096765
  15. Wu WK, Lee CW, Cho CH, et al (2010). MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene, 29, 5761-71. https://doi.org/10.1038/onc.2010.352
  16. Yamasaki T, Yoshino H, Enokida H, et al (2012). Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol, 40, 1821-30.
  17. Zhang X, Cui L, Ye G, et al (2012). Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol, 33, 2349-55. https://doi.org/10.1007/s13277-012-0497-x